Now showing items 1-1 of 1

    • Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. 

      Turkington, RC; Knight, LA; Blayney, JK; Secrier, M; Douglas, R; Parkes, EE; Sutton, EK; Stevenson, L; McManus, D; Halliday, S; McCavigan, AM; Logan, GE; Walker, SM; Steele, CJ; Perner, J; Bornschein, J; MacRae, S; Miremadi, A; McCarron, E; McQuaid, S; Arthur, K; James, JA; Eatock, MM; O'Neill, R; Noble, F; Underwood, TJ; Harkin, DP; Salto-Tellez, M; Fitzgerald, RC; Kennedy, RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group (2019-11)
      Objective Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response following ...